Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Eureka Therapeutics

Eureka Therapeutics

Eureka Therapeutics is a biotechnology company developing immunotherapies for the treatment of cancer

Eureka Therapeutics is a clinical-stage biopharmaceutical company that has the goal of curing cancer by developing novel T-cell therapies that harness the evolutionary power of the immune system.

The company believes that T-cell therapy represents a revolutionary step towards providing a potential cure for several forms of cancer, including cancers that are poorly addressed by the current approaches. Eureka's mission is to develop safe and effective T-cell therapies that are broadly accessible to the patients as the standard of care for the treatment of several hematologic and solid tumors.

The company’s proprietary ARTEMIS® platform was created to mimic the natural biology of T-cells to fight cancer. Its ARTEMIS® platform is a novel T-cell therapy construct, that is intended to create safer and potentially more effective T-cell therapies than are currently available.

Eureka's proprietary E-ALPHA® antibody discovery platform comprises of a diverse human-derived antibody phage library of over 100 billion clones with unique antibody sequences and a robust workflow that is designed to enable the company to develop specific antibodies against target antigens, including peptide-MHC complexes and cell surface proteins.

Eureka Therapeutics is currently developing a pipeline of novel cancer therapeutics targeting intracellular and cell-surface targets.

Timeline

March 17, 2020
Eureka Therapeutics raises a $45,000,000 series E round.
January 2018
Eureka Therapeutics raises a $60,000,000 series D round from Acorn Pacific Ventures and GP Capital.
2006
Eureka Therapeutics was founded.

Funding rounds

Patents

Further Resources

Title
Author
Link
Type
Date

Eureka Therapeutics Announces Data Presentations Validating Its Proprietary E-ALPHA Discovery Platform at the 2018 ASH Annual Meeting

Business Wire

Web

Eureka Therapeutics Closes $60 Million in Series D Financing to Advance Proprietary ARTEMIS™ T Cell Receptor Platform for Safer T Cell Therapies

Business Wire

Web

Eureka Therapeutics Inc. and Boehringer Ingelheim Announce a Collaboration to Identify Next Generation Antibodies for Cancer Treatment

Dr Reinhard Malin

Web

Eureka Therapeutics raises $21 million in Series C to expand cancer immunotherapy pipeline

EUREKA THERAPEUTICS, INC.

Web

News

Title
Author
Date
Publisher
Description
Alex Keown
July 7, 2021
BioSpace
This morning, multiple companies announced clinical and strategic collaborations to develop novel therapies and treatments for various diseases. Here are some of them.
Kyle LaHucik
July 6, 2021
FierceBiotech
Sanofi will fork over an undisclosed upfront payment but a major $1 billion in biobucks to Eureka and Memorial Sloan Kettering for the exclusive rights to a potential treatment for multiple myeloma.
Angus Liu
December 10, 2020
FierceBiotech
The respiratory airway, as the primary entry point of the novel coronavirus, could be a good target for delivery of drugs that aim to protect people against the disease. An antibody nasal spray designed by Eureka Therapeutics protected mice against the virus for at least 10 hours, even at the lowest concentrations tested.
BioSpace
November 9, 2020
BioSpace
Eureka Therapeutics, Inc. , a clinical stage biotechnology company developing novel T cell therapies to treat solid tumors, announced today that Randy Schekman, Ph.D., has been appointed to its Scientific Advisory Board. Dr. Schekman shared the 2013 Nobel Prize for Physiology or Medicine for his ground-breaking work on cell membrane vesicle trafficking. He is currently a Professor in the Department of Molecular and Ce

References

Golden logo
By using this site, you agree to our Terms & Conditions.